[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 685292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1063565, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 54000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 46, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 714747, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Parker", "age": 59, "title": "Executive VP & CFO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 47, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 40, "title": "SVP & Corporate Controller", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.11, "open": 1.1, "dayLow": 1.1, "dayHigh": 1.18, "regularMarketPreviousClose": 1.11, "regularMarketOpen": 1.1, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.18, "payoutRatio": 0.0, "beta": 0.36, "forwardPE": -0.8273381, "volume": 2286555, "regularMarketVolume": 2286555, "averageVolume": 4030920, "averageVolume10days": 3810270, "averageDailyVolume10Day": 3810270, "bid": 1.11, "ask": 1.19, "bidSize": 2, "askSize": 6, "marketCap": 255163136, "fiftyTwoWeekLow": 0.86, "fiftyTwoWeekHigh": 3.78, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.1952, "twoHundredDayAverage": 1.59395, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 69040184, "profitMargins": 0.0, "floatShares": 164975201, "sharesOutstanding": 221880992, "sharesShort": 24472217, "sharesShortPriorMonth": 25930643, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.1103, "heldPercentInsiders": 0.1745, "heldPercentInstitutions": 0.74087, "shortRatio": 4.64, "shortPercentOfFloat": 0.1331, "impliedSharesOutstanding": 221880992, "bookValue": 1.565, "priceToBook": 0.73482424, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -236908000, "trailingEps": -1.14, "forwardEps": -1.39, "enterpriseToEbitda": -0.302, "52WeekChange": -0.5362903, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 1.15, "targetHighPrice": 14.0, "targetLowPrice": 1.6, "targetMeanPrice": 7.56, "targetMedianPrice": 7.5, "recommendationKey": "none", "numberOfAnalystOpinions": 10, "totalCash": 273120000, "totalCashPerShare": 1.231, "ebitda": -228519008, "totalDebt": 86997000, "quickRatio": 8.676, "currentRatio": 8.924, "totalRevenue": 0, "debtToEquity": 25.249, "revenuePerShare": 0.0, "returnOnAssets": -0.26976, "returnOnEquity": -0.55121, "grossProfits": -180040992, "freeCashflow": -95369872, "operatingCashflow": -172772000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 3.6036, "regularMarketPrice": 1.15, "postMarketTime": 1757113449, "regularMarketTime": 1757102401, "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "longName": "Allogene Therapeutics, Inc.", "priceEpsCurrentYear": -1.1316112, "fiftyDayAverageChange": -0.04519999, "fiftyDayAverageChangePercent": -0.037817933, "twoHundredDayAverageChange": -0.44395006, "twoHundredDayAverageChangePercent": -0.27852196, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539264600000, "postMarketChangePercent": 0.8521806, "postMarketPrice": 1.1598, "postMarketChange": 0.0098000765, "regularMarketChange": 0.04, "regularMarketDayRange": "1.1 - 1.18", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 4030920, "fiftyTwoWeekLowChange": 0.28999996, "fiftyTwoWeekLowChangePercent": 0.33720925, "fiftyTwoWeekRange": "0.86 - 3.78", "fiftyTwoWeekHighChange": -2.63, "fiftyTwoWeekHighChangePercent": -0.6957672, "fiftyTwoWeekChangePercent": -53.62903, "earningsTimestamp": 1755115200, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "earningsCallTimestampStart": 1755118800, "earningsCallTimestampEnd": 1755118800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.14, "epsForward": -1.39, "epsCurrentYear": -1.01625, "shortName": "Allogene Therapeutics, Inc.", "corporateActions": [], "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]